Chemotherapy News and Research

Latest Chemotherapy News and Research

Multiple studies demonstrate use of hyperthermia therapy in treating pancreatic cancer

BSD Medical Corporation has began to report highlights from 204 abstracts summarizing presentations at the International Congress on Hyperthermic Oncology (ICHO) conducted this month in Munich, Germany

24 Apr 2008

Brain tumor care, treatment in spotlight

Patients, physicians, and those caring for loved ones with brain tumors will have an opportunity to attend two full days of programs hosted by health care professionals from the University of Rochester Medical Center.

24 Apr 2008

Discovery of new cell targets for preventing growth of breast and other tumors

Researchers at the Lineberger Comprehensive Cancer Center at the University of North Carolina at Chapel Hill have discovered new targets for cancer treatment aimed at blocking a key step in tumor progression.

23 Apr 2008

Slowing the spread of cancer in Albania

Once locked in decades of isolation, Albania is seeing new horizons in the fight against poverty. Expectations run high, driving demands for better - and healthier - lives.

23 Apr 2008

MacroChem acquires Virium Pharmaceuticals

MacroChem Corporation announced today that on April 18, 2008 it acquired Virium Pharmaceuticals Inc., a non-public, development stage company developing and commercializing novel therapeutics, with a portfolio of clinical stage product candidates focused in oncology, including its next generation nucleoside analogue licensed from the Southern Research Institute.

23 Apr 2008

Cisplatin found to be less effective than standard treatment for patients with anal cancer

When administered before chemoradiation, the common anti-cancer drug cisplatin neither improved disease-free survival nor reduced the number of colostomies needed when compared to the standard treatment for patients with anal canal cancer, according to a study published in the April 23 issue of the JAMA, the Journal of the American Medical Association.

22 Apr 2008

Discovery of protein that helps predict prostate cancer survival

An Oregon Health & Science University Cancer Institute researcher has identified a protein that is a strong indicator of survival for men with advanced prostate cancer. The C-reactive protein, also known as CRP, is a special type of protein produced by the liver that is elevated in the presence of inflammation.

22 Apr 2008

New advance in use of oncolytic viruses as novel cancer treatments

Combining a herpes virus genetically altered to express a drug-enhancing enzyme with a chemotherapy drug effectively and safely reduced the size of highly malignant human sarcoma grafted into mice.

22 Apr 2008

Lorus initiates development program exploring novel route of administration for LOR-2040

Lorus Therapeutics Inc. today announced the start of a development program aimed at expanding the therapeutic application of its lead clinical-stage drug LOR-2040 for the treatment of superficial bladder cancer.

22 Apr 2008

Combo of Herceptin and chemo a cure for breast cancer

The latest research has shown that the combination of Herceptin and chemotherapy drugs is successful in treating women with aggressive breast cancer.

22 Apr 2008

Vitamin D protects women from breast cancer

The connection between vitamin D levels and certain forms of cancer has been suspected for some time but now German researchers have come up with clear proof of the link.

21 Apr 2008

Cancer could return unless stored ovarian tissue undergoes adequate testing before re-implantation

Cancer patients who have been successfully treated for their disease face the prospect of its return if stored ovarian (or testicular) tissue is transplanted back into their bodies without adequate checks, according to researchers at two university hospitals in Israel.

21 Apr 2008

Chemotherapy causes delayed severe neural damage

Cancer treatment with chemotherapeutic agents is often associated with delayed adverse neurological consequences - an occurrence often referred to as "chemobrain" - that may compromise the quality of life of a proportion of cancer survivors.

21 Apr 2008

Genentech updates on phase III study of Avastin plus chemo in first-line, advanced, non-squamous, non-small cell lung cancer

Genentech, Inc. has announced an update for the previously reported Roche-sponsored international Phase III clinical study (AVAiL) of Avastin (bevacizumab) in combination with gemcitabine and cisplatin chemotherapy, in patients with advanced, non-squamous, non-small cell lung cancer (NSCLC).

21 Apr 2008

The limits of observational data in determining outcomes from cancer therapy

Certain biases may exist in observational studies that compare outcomes of different cancer therapies, making the results questionable.

21 Apr 2008

Vitamin D and the risk of developing breast cancer

A connection between vitamin D level and the risk of developing breast cancer has been implicated for a long time, but its clinical relevance had not yet been proven.

18 Apr 2008

Herceptin and chemotherapy improves response rates without major adverse effects in HER2 breast cancer

Women with a particularly aggressive form of breast cancer seem to do better if they are treated with a combined anthracycline and taxane chemotherapy regimen before surgery, together with trastuzumab (Herceptin) before and after surgery, according to results from the largest multi-centre trial to investigate this treatment.

18 Apr 2008

Yale researchers identify, characterize and clone ovarian cancer stem cells

Researchers at Yale School of Medicine have identified, characterized and cloned ovarian cancer stem cells and have shown that these stem cells may be the source of ovarian cancer’s recurrence and its resistance to chemotherapy.

17 Apr 2008

Mistletoe therapy in oncology

For many people, mistletoe conjures up images of Christmas holidays, but in parts of Europe, mistletoe extract is widely used as a therapy for cancer patients. However, a new review of studies finds only weak evidence that the treatment provides any benefit.

17 Apr 2008

New type of drug shrinks primary breast cancer tumours significantly in just six weeks

A drug that targets the cell surface receptors that play an important role in many types of cancer can bring about significant tumour regression in breast cancer after only six weeks of use, a scientist told the 6th European Breast Cancer Conference (EBCC-6) (Thursday 17 April).

17 Apr 2008